Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Check Note
Ver. Summary Created by Modification Content Size Created at Operation
1 -- 2861 2023-02-08 07:34:24 |
2 Add links Meta information modification 2861 2023-02-08 07:36:24 | |
3 format correct Meta information modification 2861 2023-02-08 07:53:44 | |
4 format correct + 32 word(s) 2893 2023-02-10 01:24:06 | |
5 format correct Meta information modification 2893 2023-02-10 07:07:14 |
Regulators of Fibrinolysis in Oral Cavity
Upload a video

The oral cavity is a unique environment that consists of teeth surrounded by periodontal tissues, oral mucosae with minor salivary glands, and terminal parts of major salivary glands that open into the oral cavity. It is a first-line defense against most viral and bacterial pathogens. Fibrinolytic factors of the plasminogen (Plg)/plasmin (Pm) system, their soluble and membrane receptors, and fragments, such as suPAR (soluble urokinase plasminogen activator receptor) modulate physiological and pathological conditions, especially inflammation.  Fibrinolysis, the removal of fibrin, is the primary function of fibrinolytic factors. Under physiological conditions, fibrinolytic factors are present in the oral cavity and secreted mostly with saliva. Under the inflammation plasminogen/plasmin system performs fibrinolytic and non-fibrinolytic functions: cytokines or proteases (MMPs) are activated, receptors such as suPAR are shed from the surface promoting cell migration, and modulation of the inflammatory response. Viruses, like SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), exploit the fibrinolytic system to promote host cell infection.

plasmin COVID-19 suPAR oral cavity
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , , , , , ,
View Times: 150
Revisions: 5 times (View History)
Update Date: 10 Feb 2023
Table of Contents

    1. Introduction

    The primary function of the plasminogen (Plg/Pm) system is to ensure the destruction of fibrin deposits and maintain hemostatic balance. Hemostasis is the process of blood clot formation at the site of vessel injury. There is a careful balance between thrombin-stimulated clot formation and plasmin-induced clot lysis. Abnormal bleeding occurs when there is insufficient clot formation due to decreased thrombin (e.g., from F VIII deficiency) or increased clot lysis. Conversely, non-physiological thrombosis or functional clotting occurs when excessive thrombin production or impaired clot lysis is present. During the initial phase of hemostasis after tissue damage, endothelial injury induces platelet aggregation within 10–20 s. The sequential activation of coagulation factors (XIII-II) generates an initial hemostatic plug in 1–3 min. Fibrin, produced at the end of the coagulation cascade, adds to the clot stability by 5–10 min. Since a clot should only obstruct the vessel for a particular time, the body switches from clotting to antithrombotic control mechanisms. The activation of plasmin that leads to fibrin degradation and the occurrence of fibrin degradation fragments, a process called fibrinolysis, ultimately removes the clot to ensure tissue blood reperfusion (Figure 1).
    Figure 1. Non-fibrinolytic and fibrinolytic functions of the plasminogen/plasmin system. Binding and subsequent plasminogen activation via plasminogen receptors (Plg-RKT, annexin 2, actin, etc.) generate plasmin. Plasmin induces proteolytic activity on the cell surface to cleave the extracellular matrix molecules necessary for cell migration. Plasmin generated by tPA on polymer fibrin, uPA, or clotting factors on activated cell surfaces dissolves fibrin and produces fibrin fragments such as D-dimers. This process is called fibrinolysis. The non-fibrinolytic functions of plasmin include proteolytic activity towards latent growth factors, the complement component C5, and pro-MMPs resulting in changes in molecule-linked signaling pathways. The cleavage of plasmin, elastase, and MMPs generate angiostatins–kringle-containing plasminogen fragments possessing anti-angiogenic properties. Abbreviations: Pm, plasmin; tPA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; ECM, extracellular matrix; MMPs, matrix metalloproteinases; suPAR, soluble urokinase plasminogen activator receptor; α2AP, α2-antiplasmin; α2MG, α2-macroglobulin.
    Besides the fibrinolytic function, the Plg/Pm system can alter cell receptors, extracellular matrix molecules, or growth factors due to its proteolytic capacity. In addition, components of the Plg/Pm system participate in intracellular signaling processes, thus regulating tissue development and remodeling during wound healing, inflammation, trophoblast invasion, angiogenesis, tumor growth, etc. [1][2][3][4][5]. These functions are referred to as non-fibrinolytic functions (Figure 1).
    There are two major plasminogen activators (PAs) that can activate Plg in humans: tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Both PAs are serine proteinases of the trypsin type. However, differences in their structure cause functional differences: tPA mainly converts Plg to plasmin on fibrin clots, while the activity of uPA is regulated by its interaction with the cell surface [6][7]. Plg activation is involved in tissue remodeling and inflammatory response (reviewed in [8][9]). Plg levels are high at the inflammation site and regulate the wound-healing process by activating the early inflammatory reaction [10] by increasing inflammatory cell infiltration.
    “Health comes first, and it enters through the mouth”. The mouth, in academic terms, is referred to as the oral cavity [8]. The oral cavity is a structure of tissues and organs with complex organization and interaction. Initial parts of the digestive system, the immune system (Waldeyer’s tonsillar ring), and sensory-specific and non-specific receptors (taste, temperature, pain, tactile sensation, etc.) are located in the oral cavity. Both the nasal cavity and nasopharynx, as the beginning of the respiratory system, and the oral cavity are the entrance gateway for bacterial and viral infections. The first signs and symptoms of general infectious and non-infectious diseases can occur in the oral cavity (loss of taste or hemorrhagic rash on soft palatine mucosae in COVID-19 (coronavirus disease 2019), Koplik’s sign in measles, oral dryness and the decaying of multiple teeth in diabetes mellitus, etc.). The oral cavity environment is very sensitive to systemic and local changes in the organism and reacts to pathogen exposure with quantitative and qualitative changes in saliva and crevicular fluid. The Plg/Pm system of the oral fluid plays an integral part in the physiological regeneration and protective mechanisms of oral mucosae, the pathogenesis of several inflammatory or autoimmune diseases, and tumor growth in the oral cavity [11].

    2. Regulators of Fibrinolysis

    The Plg/Pm system includes the proteolytic enzyme plasmin and its inactive precursor Plg, its activators (tPA and uPA), plasmin inhibitors (α2-antiplasmin and α2-macroglobulin), and inhibitors of plasminogen activators (PAI-1 and PAI-2) [12]. These components regulate and interact with each other as well as with clotting system components, cell receptors, and pericellular adhesion molecules (Figure 1) [5]. In addition, many proteins can modulate the activity of the fibrinolytic system components: proteins such as vitronectin, thrombospondin, tetranectin, and histidine-rich glycoprotein, which can bind to Plg/Pm, fibrinolysis activators, or inhibitors.
    PAs and components of the clotting cascade mediate Plg conversion to active plasmin. The tissue activator generates plasmin on fibrin and cell surface. Activation of Plg by uPA occurs on the cell surface in blood circulation or outside of it [6][12]. Like thrombin, plasmin activates protease-activated receptor (PAR)1 and PAR2, modulating platelet activation, the release of proinflammatory cytokines by immune cells, and endothelial function [13].

    2.1. Plasminogen (Plg)

    The inactive proenzyme Plg and its active derivative plasmin are key components of the fibrinolytic system. Plasmin belongs to the serine protease family of enzymes. Plg is secreted into the bloodstream mainly by hepatocytes and the kidney epithelium and can be synthesized and utilized out of circulation in the cornea [14]. Interleukin (IL)-1a and -1b can stimulate the extrahepatic synthesis of Plg in the human cornea [14].
    Plg is a 92 kDa glycoprotein comprised of heavy (N-terminal domain followed by five kringle domains) and light (protease domain) chains linked by an activation loop [15]. Two glycosylated forms of Plg (I and II) vary in their number of sugar remnants, their affinity to fibrin, and their activation susceptibility [16]. Substrate or receptor binding leads to the dissociation of intramolecular bonds and proenzyme transition into an open form susceptible to activation [17][18]. Proteolytic fragmentation of the Plg/Pm molecule produces kringle-containing fragments such as angiostatins [19][20]. Angiostatins bind to plasminogen receptors or the hepatocyte growth factor receptor c-met. This binding results in the blockade of proliferation or angiogenesis and the induction of apoptosis [21].
    α2-antiplasmin and α2-macroglobulin [22][23] are natural plasmin inhibitors (Figure 1).
    Proteolytically active plasmin has a broad specificity. It modulates the release and activation status of growth factors/cytokines (e.g., TGF-β, fibroblast growth factor-2 [24][25], hepatocyte growth factor [26], insulin-like growth factor-binding protein 4, and IL-1β [5]), hormones (e.g., prolactin [27], lactogen, osteocalcin [28], pro-opiomelanocortin [29], proinsulin [30][31]), receptors (e.g., uPAR [32] and EPH receptor A4), and proteases (e.g., tPA, uPA, and MMPs [33][34]) (Figure 1).
    Plg and plasmin activators binding to annexin A2, urokinase plasminogen activator receptor (uPAR), and other docking sites colocalize enzyme and substrate, generating efficient plasmin at cell surfaces. Plg receptors can mediate the fibrinolytic function of this system and signal transmission inside the cell. Among the receptors for plasminogen on the cell surface are the highly specific Plg-RKT (plasminogen receptor with a C-terminal lysine) and the less specific αIIbβ3-integrin, αMβ2, αVβ3, α-enolase, gamma-actin, S100A10, annexin 2, histone H2B, amphoterin, or PAR. Aside from receptors, Plg interacts with partner proteins, such as fibrinogen/fibrin or tetranectin on cell surfaces [22][35]. Plg-RKT is expressed on monocytes, macrophages, and neuronal cells. It is sterically close to uPAR, providing conditions for plasmin generation and the Plg/Pm-dependent inflammatory response [36][37]. At the same time, annexin A2 reduces plasmin production and facilitates the autoproteolytic destruction of plasmin [38].

    2.2. Plasminogen Activators (PAs)

    tPA activates Plg mostly on fibrin thrombi surfaces but also on some cell membranes, mediating plasmin formation for cell movement through the extracellular matrix and modulating cell signaling. uPA mainly acts on cell surfaces. However, recent research has demonstrated the involvement of both PAs and plasmin in cell signaling, migration, and extracellular matrix remodeling [5][39]. Factor XIIa, an endogenous activator of the clotting system, can activate Plg and kallikrein and convert single-chain urokinase into double-chain urokinase. Nevertheless, their role in physiological fibrinolysis is considered insignificant [40].
    tPA: tPA (tissue-type plasminogen activator, Plat gene) is a 70-kDa glycoprotein belonging to the serine protease family. tPA is synthesized mainly by endothelial cells, but mesenchymal cells, monocytes, smooth muscle cells, and fibroblasts can also produce it [41]. It is the primary PA (>90%) in all tissues except the kidney and liver (65%) and the spleen (40%). Lung tissues yield the highest tPA activity, followed by kidney, brain, heart, adrenal, liver, aorta, spleen, and muscle tissue [42]. In addition, stress, adrenergic stimulation, the diurnal cycle (and other circadian cycles), histamine, and thrombin enhance the synthesis and release of tPA. Most tPA in circulation exists in a complex with its primary inhibitor, PAI-1. tPA has a short half-life (3–4 min) and is removed from the bloodstream by the liver via mannose receptors [41][43]. The serine proteinase domain of tPA has a narrow specificity for Plg activation. In addition, the PAI-1 binding site is located in the serine proteinase domain of the tissue activator [44][45][46].
    Besides having fibrinolytic functions, tPA can modulate cell signaling due to its ability to activate Plg on the cell surface or interact with specific receptors (reviewed in [8]). tPA-related signaling accelerates ischemic revascularization and regulates synaptic plasticity, blood-brain barrier permeability, cytokine production, cell proliferation, etc. tPA can affect cell fate alone or as part of the PAI-1/tPA complex [47]. The binding of tPA to Annexin A2 enhances proinflammatory cytokine production by macrophages through the generation of active plasmin and subsequent matrix metalloprotease-9 activation [48]. In addition, it stimulates endothelial progenitor cell evasion from the bone marrow [49].
    The interaction of tPA with the low-density lipoprotein-related protein-1 (LRP1) receptor triggers cell survival and proliferation [39]. After binding to the membrane receptor LRP1, tPA-mediated NF-κB activation increases the expression of proinflammatory chemokines in macrophages [50]. tPA triggers a cascade of survival signaling involving extracellular signal-regulated kinase 1/2 [51]. In macrophages, enzymatically non-active tPA inhibits toll-like receptors through the N-methyl-D-aspartate receptor [52].
    uPA: uPA (Plau gene) is a 54-kDa glycoprotein, synthesized as a single chain (sc-uPA) and converted into a two-chain uPA (tc-uPA) by plasmin and kallikrein [41]. The uPA molecule contains a protease, EGF, and a kringle domain without a lysine binding site which ensures that it cannot bind to fibrin [53].
    Further proteolysis of sc- or tc-uPA by plasmin or matrix metalloproteases (MMPs) generates an amino-terminal fragment (ATF) that consists of the EGF and kringle domain (33 or 32 kDa) [54]. The ATF can bind to the primary uPA receptor called uPAR. Thrombin cleaves the Arg156–Phe157 peptide bond near the active site and generates another proteolytic two-chain inactive uPA [55]. Recent studies have demonstrated that soluble uPAR (suPAR) dimers, but not monomers, have a stronger binding ability to the ATF of uPA [56].

    2.3. Plasminogen Activator Inhibitors

    Fibrinolysis shutdown is provided by plasmin inhibitors, plasminogen activator inhibitors, and indirect fibrinolysis inhibitors. α2-antiplasmin and α2-macroglobulin [22][23] are naturally occurring specific plasmin inhibitors (Figure 1). Fibrin-bound plasmin and receptor-bound plasmin are protected from inactivation by plasmin inhibitors [7]. Indirect inhibitors (e.g., thrombin-activated fibrinolysis inhibitor, TAFI) regulate the rate of clot dissolution by fibrin modification [57]. However, the most abundant fibrinolysis inhibitor in circulation is PAI-1, a glycoprotein that belongs to serine protease inhibitors (SERPINs) and is, therefore, also called serpin E1. PAI-1 can be found in blood, soft tissues, tissues of the parenchymal organs, vessel walls, nervous tissue, etc. [58].
    The primary function of PAI-1 in the bloodstream is to inhibit tPA and uPA, thus regulating the rate of fibrinolysis and the duration of blood clots. In tissues, PAI-1 also performs a signaling function and participates in the regulation of cell migration [59]. PAI-1 is synthesized in the liver and spleen epithelium, adipocytes, hepatocytes, platelets, megakaryocytes, macrophages, smooth muscle cells, and placental and endothelial cells [58]. In addition, pathological conditions can enhance PAI-1 expression in plasma (2–46 ng/mL) and other tissues. PAI-1 expression and release by cells such as platelets are regulated by various factors: growth factors (e.g., transforming growth factor-β (TGF-β), EGF (epidermal growth factor), PDGF (platelet-derived growth factor), tumor necrosis factor (TNF)-α, and interleukin-1 (IL-1)β), hormones (e.g., insulin, glucocorticoids, and angiotensin II), the glucosides and endotoxins of gram-negative bacteria, low-density lipoprotein, and very low-density lipoprotein [60].
    PAI-1 is a single-chain glycoprotein with a mass of 47–50 kDa [61]. PAI-1 exists in several conformational forms. In addition to the active and inactive forms, there is also a latent form. PAI-1, synthesized as an active enzyme, is spontaneously transformed into an inactive form with a half-life of 1 to 2 h. PAI-1 is the only serpin that can perform a reverse conformational transition between active and latent states. In plasma, the active form of PAI-1 can be stabilized by binding to vitronectin, thereby increasing its half-life in the bloodstream. On the other hand, PAI-1 activity rapidly decreases at lower pH, as has been found in ischemic tissues [59].

    3.3. Soluble uPAR, a New Biomarker of Inflammation

    uPAR (CD87; Plasminogen Activator, Urokinase Receptor [Plaur gene]) is a membrane-linked protein found in immunologically active cells (monocytes, neutrophils, activated T lymphocytes, macrophages), endothelial cells, keratinocytes, fibroblasts, smooth muscle cells, megakaryocytes, and certain tumor cells. Apart from uPA, uPAR can also interact with integrin or other partners, including vitronectin, high molecular weight kininogen, G protein-coupled receptor, tyrosine kinase receptors that can trigger plasmin generation and degradation of the extracellular matrix (ECM) along the leading edge of a migratory cell [62] and activate downstream signaling pathways. uPA via plasmin can increase cell proliferation through the proteolytic activation of growth factors and adhesion molecules, remodeling of tissues/ECM, regulate adhesion and invasion of normal and cancer cells [63].

    Cleavage of uPAR at the GPI (glycosyl phosphatidylinositol) anchor by proteases like plasmin can shed the extracellular part of uPAR, releasing the soluble form of the receptor (suPAR) into the blood, mucosa, urine, and saliva [64].

    3. Fibrinolytic Factors During Inflammation in the Oral Cavity

    Lined with keratinized and non-keratinized stratified squamous epithelium, oral mucosa covers the oral cavity. It is moistened with excretes of the major parotid, submandibular, sublingual, and minor salivary glands within the oral cavity. Mechanical mucosal trauma occurs while eating, drinking, and talking (and even tobacco inhalation). Oral mucosa is a first-line defense that interacts with pathogens (e.g., bacteria, viruses, or fungi) and provides specific (immune) or non-specific protective response against pathogenic microorganisms such as pattern recognition receptors including C-type lectin receptors (Dectin-1, Dectin-2) or TLR1-1 (TLRs, toll-like receptors). Gradual desquamation of mucosal epithelium is a protective mechanism to eliminate adherent pathogenic microorganisms and to prevent their further invasion into underlying tissues [65]. A host organism reacts with the release of proinflammatory cytokines and proteases to fight oral microorganisms in the gingiva and periodontal ligament space.

    Salivary glands provide local mucosal-specific and non-specific immunity. Proper qualitative and quantitative composition of saliva and salivation rate protect and maintain the integrity of the oral cavity. Salivary mucins avert plaque formation on teeth surfaces via bacteria binding. Salivary lysozyme, an enzyme that lyses bacteria cell walls prevent the overgrowth of oral microbiota. Several studies are available regarding the fibrinolytic properties of salivary glands and other fluids of the oral cavity [66] during steady state and stress/inflammation. 

    Salivary suPAR, tumor necrosis factor α (TNF α), and interleukins like (IL)-1β levels increased in healthy subjects exposed to psychological stress [76] and showed strong positive baseline and post-stress correlations. Elevated saliva suPAR levels were detected and proposed as a biomarker of gingivitis and periodontitis [67][68]. Aside from suPAR, Plg receptors such as glyceraldehyde-3-phosphate dehydrogenase, α-enolase, and annexin A2 are also found in the saliva [69][70][71][72], but their function in the oral cavity remains unclear. Excretory ducts and acinar cells highly expressed PAI-2. tPA was expressed in serous but not mucous acini [66]. Overall, several independent studies confirmed the existence of tPA in saliva, but the results of different investigators varied on the presence/dominance of PAI-1 or PAI-2 in salivary gland tissues. PAI-1 increases in saliva were associated with insulin resistance and inflammation and ascribed as a proinflammatory marker and valuable diagnostic marker to track periodontal therapy [73]

    Major and minor salivary glands, oral mucosae, and periodontium play an important role in maintaining oral cavity Plg/Pm system balance. Oral cavity chronic diseases and hyposalivation cause a dysbalance of the Plg/Pm system in the oral cavity, supporting inflammation. Viruses, including SARS-CoV2, enter the body via the oral and nasal cavities, where the initial replication of viruses occurs. The non-fibrinolytic proteolytic function of plasmin supports the initial stages of infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). For example, the SARS-CoV-2 virus can enter the buccal epithelium after binding its S protein to ACE2. Plasmin cleaves the S-protein of the SARS-CoV-2 virus and ENaC (epithelial Na+ channel) α, β, γ, and facilitates SARS-CoV-2 infection into susceptible cells (non-fibrinolytic function). 


    1. Bharadwaj, A.G.; Holloway, R.W.; Miller, V.A.; Waisman, D.M. Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy. Cancers 2021, 13, 1838.
    2. Heissig, B.; Salama, Y.; Osada, T.; Okumura, K.; Hattori, K. The Multifaceted Role of Plasminogen in Cancer. Int. J. Mol. Sci. 2021, 22, 2304.
    3. Heissig, B.; Ohki-Koizumi, M.; Tashiro, Y.; Gritli, I.; Sato-Kusubata, K.; Hattori, K. New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis. Int. J. Hematol. 2012, 95, 131–137.
    4. Medcalf, R.L.; Keragala, C.B. The Fibrinolytic System: Mysteries and Opportunities. HemaSphere 2021, 5, e570.
    5. Myöhänen, H.; Vaheri, A. Regulation and interactions in the activation of cell-associated plasminogen. Cell. Mol. Life Sci. CMLS 2004, 61, 2840–2858.
    6. Rijken, D.C.; Lijnen, H.R. New insights into the molecular mechanisms of the fibrinolytic system. J. Thromb. Haemost. 2009, 7, 4–13.
    7. Urano, T.; Castellino, F.J.; Suzuki, Y. Regulation of plasminogen activation on cell surfaces and fibrin. J. Thromb. Haemost. 2018, 16, 1487–1497.
    8. Heissig, B.; Salama, Y.; Takahashi, S.; Osada, T.; Hattori, K. The multifaceted role of plasminogen in inflammation. Cell. Signal. 2020, 75, 109761.
    9. Baker, S.K.; Strickland, S. A critical role for plasminogen in inflammation. J. Exp. Med. 2020, 217, e20191865.
    10. Shen, Y.; Guo, Y.; Mikus, P.; Sulniute, R.; Wilczynska, M.; Ny, T.; Li, J. Plasminogen is a key proinflammatory regulator that accelerates the healing of acute and diabetic wounds. Blood 2012, 119, 5879–5887.
    11. Kessler, A.T.; Bhatt, A.A. Review of the Major and Minor Salivary Glands, Part 1: Anatomy, Infectious, and Inflammatory Processes. J. Clin. Imaging Sci. 2018, 8, 47.
    12. Rijken, D.C.; Sakharov, D.V. Basic Principles in Thrombolysis: Regulatory Role of Plasminogen. Thromb. Res. 2001, 103, S41–S49.
    13. Pryzdial, E.L.G.; Leatherdale, A.; Conway, E.M. Coagulation and complement: Key innate defense participants in a seamless web. Front. Immunol. 2022, 13, 918775.
    14. Twining, S.S.; Wilson, P.M.; Ngamkitidechakul, C. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-1alpha and -1beta. Biochem. J. 1999, 339 Pt 3, 705–712.
    15. Castellino, F.J.; McCance, S.G. The Kringle Domains of Human Plasminogen. In Ciba Foundation Symposium 212—Plasminogen-Related Growth Factors; Novartis Foundation Symposia; John Wiley & Sons: Hoboken, NJ, USA, 2007; pp. 46–65.
    16. Rudd, P.M.; Woods, R.J.; Wormald, M.R.; Opdenakker, G.; Downing, A.K.; Campbell, I.D.; Dwek, R.A. The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator. Biochim. Biophys. Acta (BBA)—Protein Struct. Mol. Enzymol. 1995, 1248, 1–10.
    17. Zhang, L.; Gong, Y.; Grella, D.K.; Castellino, F.J.; Miles, L.A. Endogenous plasmin converts Glu-plasminogen to Lys-plasminogen on the monocytoid cell surface. J. Thromb. Haemost. 2003, 1, 1264–1270.
    18. Silverstein, R.L.; Friedlander, R.J., Jr.; Nicholas, R.L.; Nachman, R.L. Binding of Lys-plasminogen to monocytes/macrophages. J. Clin. Investig. 1988, 82, 1948–1955.
    19. Cao, Y.; Xue, L. Angiostatin. Semin. Thromb. Hemost. 2004, 30, 83–93.
    20. O’Reilly, M.S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R.A.; Moses, M.; Lane, W.S.; Cao, Y.; Sage, E.H.; Folkman, J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell 1994, 79, 315–328.
    21. Syed, S.P.; Martin, A.-M.; Haupt, H.M.; Arenas-Elliot, C.P.; Brooks, J.J. Angiostatin receptor annexin II in vascular tumors including angiosarcoma. Hum. Pathol. 2007, 38, 508–513.
    22. Yatsenko, T.A.; Rybachuk, V.M.; Yusova, O.I.; Kharchenko, S.M.; Grinenko, T.V. Effect of fibrin degradation products on fibrinolytic process. Ukr. Biochem. J. 2016, 88, 16–24.
    23. Schneider, M.; Nesheim, M. A Study of the Protection of Plasmin from Antiplasmin Inhibition within an Intact Fibrin Clot during the Course of Clot Lysis. J. Biol. Chem. 2004, 279, 13333–13339.
    24. Lamarre, J.; Vasudevan, J.; Gonias, S.L. Plasmin cleaves betaglycan and releases a 60 kDa transforming growth factor-β complex from the cell surface. Biochem. J. 1994, 302, 199–205.
    25. Sahni, A.; Francis, C.W. Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J. Thromb. Haemost. 2003, 1, 1271–1277.
    26. Matsuoka, H.; Sisson, T.H.; Nishiuma, T.; Simon, R.H. Plasminogen-Mediated Activation and Release of Hepatocyte Growth Factor from Extracellular Matrix. Am. J. Respir. Cell Mol. Biol. 2006, 35, 705–713.
    27. Friedrich, C.; Neugebauer, L.; Zamora, M.; Robles, J.P.; Martínez de la Escalera, G.; Clapp, C.; Bertsch, T.; Triebel, J. Plasmin generates vasoinhibin-like peptides by cleaving prolactin and placental lactogen. Mol. Cell. Endocrinol. 2021, 538, 111471.
    28. Novak, J.F.; Hayes, J.D.; Nishimoto, S.K. Plasmin-Mediated Proteolysis of Osteocalcin. J. Bone Miner. Res. 1997, 12, 1035–1042.
    29. Wang, N.; Zhang, L.; Miles, L.; Hoover-Plow, J. Plasminogen regulates pro-opiomelanocortin processing. J. Thromb. Haemost. 2004, 2, 785–796.
    30. Ishii, T.; Fukano, K.; Shimada, K.; Kamikawa, A.; Okamatsu-Ogura, Y.; Terao, A.; Yoshida, T.; Saito, M.; Kimura, K. Proinsulin C-peptide activates α-enolase: Implications for C-peptide–cell membrane interaction. J. Biochem. 2012, 152, 53–62.
    31. Okaji, Y.; Tashiro, Y.; Gritli, I.; Nishida, C.; Sato, A.; Ueno, Y.; Del Canto Gonzalez, S.; Ohki-Koizumi, M.; Akiyama, H.; Nakauchi, H.; et al. Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis. Exp. Hematol. 2012, 40, 143–154.
    32. Magnussen, S.N.; Hadler-Olsen, E.; Costea, D.E.; Berg, E.; Jacobsen, C.C.; Mortensen, B.; Salo, T.; Martinez-Zubiaurre, I.; Winberg, J.O.; Uhlin-Hansen, L.; et al. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: Regulation by transforming growth factor—beta1 (TGF-beta1) and potential effects on migration and invasion. BMC Cancer 2017, 17, 350.
    33. Monea, S.; Lehti, K.; Keski-Oja, J.; Mignatti, P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell. Physiol. 2002, 192, 160–170.
    34. Heissig, B.; Lund, L.R.; Akiyama, H.; Ohki, M.; Morita, Y.; Rømer, J.; Nakauchi, H.; Okumura, K.; Ogawa, H.; Werb, Z.; et al. The Plasminogen Fibrinolytic Pathway Is Required for Hematopoietic Regeneration. Cell Stem Cell 2008, 3, 120.
    35. Plow, E.F.; Doeuvre, L.; Das, R. So Many Plasminogen Receptors: Why? J. Biomed. Biotechnol. 2012, 2012, 141806.
    36. Miles, L.A.; Vago, J.P.; Sousa, L.P.; Parmer, R.J. Functions of the plasminogen receptor Plg-RKT. J. Thromb. Haemost. 2020, 18, 2468–2481.
    37. Bharadwaj, A.G.; Kempster, E.; Waisman, D.M. The ANXA2/S100A10 Complex—Regulation of the Oncogenic Plasminogen Receptor. Biomolecules 2021, 11, 1772.
    38. Bharadwaj, A.; Kempster, E.; Waisman, D.M. The Annexin A2/S100A10 Complex: The Mutualistic Symbiosis of Two Distinct Proteins. Biomolecules 2021, 11, 1849.
    39. Salama, Y.; Lin, S.Y.; Dhahri, D.; Hattori, K.; Heissig, B. The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis. FASEB J. 2019, 33, 3465–3480.
    40. Ichinose, A.; Kisiel, W.; Fujikawa, K. Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. FEBS Lett. 1984, 175, 412–418.
    41. Sappino, A.P.; Huarte, J.; Vassalli, J.D.; Belin, D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J. Clin. Investig. 1991, 87, 962–970.
    42. Padró, T.; van den Hoogen, C.M.; Emeis, J.J. Distribution of tissue-type plasminogen activator (activity and antigen) in rat tissues. Blood Coagul. Fibrinolysis 1990, 1, 601–608.
    43. Kristensen, P.; Larsson, L.-I.; Nielsen, L.S.; Grøndahl-Hansen, J.; Andreasen, P.A.; Danø, K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 1984, 168, 33–37.
    44. Silva, M.M.C.G.; Thelwell, C.; Williams, S.C.; Longstaff, C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J. Thromb. Haemost. 2012, 10, 2354–2360.
    45. Collen, D.; Lijnen, H.R. The Tissue-Type Plasminogen Activator Story. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1151–1155.
    46. Cheng, X.-F.; Brohlin, M.; Pohl, G.; Bäck, O.; Wallén, P. Binding of tissue plasminogen activator to endothelial cells: The effect on functional properties. Localization of a ligand in the B-chain of tPA. Thromb. Res. 1995, 77, 149–164.
    47. Sashindranath, M.; Sales, E.; Daglas, M.; Freeman, R.; Samson, A.L.; Cops, E.J.; Beckham, S.; Galle, A.; McLean, C.; Morganti-Kossmann, C.; et al. The tissue-type plasminogen activator–plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: Evidence from mice and humans. Brain 2012, 135, 3251–3264.
    48. Heissig, B.; Eiamboonsert, S.; Salama, Y.; Shimazu, H.; Dhahri, D.; Munakata, S.; Tashiro, Y.; Hattori, K. Cancer therapy targeting the fibrinolytic system. Adv. Drug Deliv. Rev. 2016, 99, 172–179.
    49. Leu, S.; Day, Y.-J.; Sun, C.-K.; Yip, H.-K. tPA-MMP-9 Axis Plays a Pivotal Role in Mobilization of Endothelial Progenitor Cells from Bone Marrow to Circulation and Ischemic Region for Angiogenesis. Stem Cells Int. 2016, 2016, 5417565.
    50. Seillier, C.; Hélie, P.; Petit, G.; Vivien, D.; Clemente, D.; Le Mauff, B.; Docagne, F.; Toutirais, O. Roles of the tissue-type plasminogen activator in immune response. Cell. Immunol. 2022, 371, 104451.
    51. Hu, K.; Lin, L.; Tan, X.; Yang, J.; Bu, G.; Mars, W.M.; Liu, Y. tPA Protects Renal Interstitial Fibroblasts and Myofibroblasts from Apoptosis. J. Am. Soc. Nephrol. 2008, 19, 503.
    52. Das, L.; Azmoon, P.; Banki, M.A.; Mantuano, E.; Gonias, S.L. Tissue-type plasminogen activator selectively inhibits multiple toll-like receptors in CSF-1-differentiated macrophages. PLoS ONE 2019, 14, e0224738.
    53. Husain, S.S. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochem.-Us 1991, 30, 5797–5805.
    54. Mahmood, N.; Mihalcioiu, C.; Rabbani, S.A. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front. Oncol. 2018, 8, 24.
    55. Bansal, V.; Roychoudhury, P.K. Production and purification of urokinase: A comprehensive review. Protein Expr. Purif. 2006, 45, 1–14.
    56. Yu, S.; Sui, Y.; Wang, J.; Li, Y.; Li, H.; Cao, Y.; Chen, L.; Jiang, L.; Yuan, C.; Huang, M. Crystal structure and cellular functions of uPAR dimer. Nat. Commun. 2022, 13, 1665.
    57. Sillen, M.; Declerck, P.J. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review. Int. J. Mol. Sci. 2021, 22, 3670.
    58. Tjärnlund-Wolf, A.; Brogren, H.; Lo, E.H.; Wang, X. Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases. Stroke 2012, 43, 2833–2839.
    59. Kubala, M.H.; DeClerck, Y.A. The plasminogen activator inhibitor-1 paradox in cancer: A mechanistic understanding. Cancer Metastasis Rev. 2019, 38, 483–492.
    60. Yasar Yildiz, S.; Kuru, P.; Toksoy Oner, E.; Agirbasli, M. Functional Stability of Plasminogen Activator Inhibitor-1. Sci. World J. 2014, 2014, 858293.
    61. Sillen, M.; Miyata, T.; Vaughan, D.E.; Strelkov, S.V.; Declerck, P.J. Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484. Int. J. Mol. Sci. 2021, 22, 1482.
    62. Smith, H.W.; Marshall, C.J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 2010, 11, 23–36.
    63. Mahmood, N.; Mihalcioiu, C.; Rabbani, S.A. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front. Oncol. 2018, 8, 24.
    64. Huang, J.; Liu, G.; Zhang, Y.; Cui, Z.; Wang, F.; Liu, X.; Chu, R.; Zhao, M. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014, 12, 81.
    65. Skrypnyk, M.; Petrushanko, T.; Neporada, K.; Vynnyk, N.; Petrushanko, V.; Skrypnyk, R. Colonization resistance of oral mucosa in individuals with diverse body mass index. J. Stomatol. 2022, 75, 171–175.
    66. Virtanen, O.J.; Sirén, V.; Multanen, J.; Färkkilä, M.; Leivo, I.; Vaheri, A.; Koskiniemi, M. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. Eur. J. Oral Sci. 2006, 114, 22–26.
    67. Skottrup, P.D.; Dahlén, G.; Baelum, V.; Lopez, R. Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents. Eur. J. Oral Sci. 2018, 126, 292–299.
    68. Taşdemir, İ.; Erbak Yılmaz, H.; Narin, F.; Sağlam, M. Assessment of saliva and gingival crevicular fluid soluble urokinase plasminogen activator receptor (suPAR), galectin-1, and TNF-α levels in periodontal health and disease. J. Periodontal Res. 2020, 55, 622–630.
    69. Wen, J.; Nikitakis, N.G.; Chaisuparat, R.; Greenwell-Wild, T.; Gliozzi, M.; Jin, W.; Adli, A.; Moutsopoulos, N.; Wu, T.; Warburton, G.; et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am. J. Pathol. 2011, 178, 2866–2878.
    70. Sejima, T.; Holtappels, G.; Bachert, C. The Expression of Fibrinolytic Components in Chronic Paranasal Sinus Disease. Am. J. Rhinol. Allergy 2011, 25, 1–6.
    71. Firinu, D.; Arba, M.; Vincenzoni, F.; Iavarone, F.; Costanzo, G.; Cabras, T.; Castagnola, M.; Messana, I.; Del Giacco, S.R.; Sanna, M.T. Proteomic Analysis of the Acid-Insoluble Fraction of Whole Saliva from Patients Affected by Different Forms of Non-histaminergic Angioedema. J. Clin. Immunol. 2020, 40, 840–850.
    72. Wang, J.; Li, Y.; Pan, L.; Li, J.; Yu, Y.; Liu, B.; Zubair, M.; Wei, Y.; Pillay, B.; Olaniran, A.O.; et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) moonlights as an adhesin in Mycoplasma hyorhinis adhesion to epithelial cells as well as a plasminogen receptor mediating extracellular matrix degradation. Vet. Res. 2021, 52, 80.
    73. Guru, S.R.; Aghanashini, S. Impact of scaling and root planing on salivary and serum plasminogen activator inhibitor-1 expression in patients with periodontitis with and without type 2 diabetes mellitus. J. Periodontol. 2023, 94, 20–30.
    Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , , , , , ,
    View Times: 150
    Revisions: 5 times (View History)
    Update Date: 10 Feb 2023
    Table of Contents


      Are you sure to Delete?

      Video Upload Options

      Do you have a full video?
      If you have any further questions, please contact Encyclopedia Editorial Office.
      Yatsenko, T.;  Skrypnyk, M.;  Troyanovska, O.;  Tobita, M.;  Osada, T.;  Takahashi, S.;  Hattori, K.;  Heissig, B. Regulators of Fibrinolysis in Oral Cavity. Encyclopedia. Available online: (accessed on 03 June 2023).
      Yatsenko T,  Skrypnyk M,  Troyanovska O,  Tobita M,  Osada T,  Takahashi S, et al. Regulators of Fibrinolysis in Oral Cavity. Encyclopedia. Available at: Accessed June 03, 2023.
      Yatsenko, Tetiana, Maksym Skrypnyk, Olga Troyanovska, Morikuni Tobita, Taro Osada, Satoshi Takahashi, Koichi Hattori, Beate Heissig. "Regulators of Fibrinolysis in Oral Cavity" Encyclopedia, (accessed June 03, 2023).
      Yatsenko, T.,  Skrypnyk, M.,  Troyanovska, O.,  Tobita, M.,  Osada, T.,  Takahashi, S.,  Hattori, K., & Heissig, B. (2023, February 08). Regulators of Fibrinolysis in Oral Cavity. In Encyclopedia.
      Yatsenko, Tetiana, et al. "Regulators of Fibrinolysis in Oral Cavity." Encyclopedia. Web. 08 February, 2023.